Phase 3 Migraine Trial, Recruiting NCT07018700 Sponsor: Merz Therapeutics GmbH Condition: Migraine
Back to Migraine

Phase 3 Migraine Trial, Recruiting

NCT07018700
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with episodic migraine (with or without aura) for at least 12 months, and you can tell the difference between your migraines and other types of headaches
  • Your migraines first started before you were 50 years old
  • In each of the 3 months before your screening appointment, you had no more than 14 headache days per month, and between 6 and 14 of those days were migraine days
  • In the last 28 days of your screening period, you experienced no more than 14 headache days, with between 6 and 14 of those being migraine days recorded in a headache diary

Who may not be able to join:

  • You have been diagnosed with chronic migraine
  • You have been diagnosed with other primary headache conditions, unless it is tension-type headache, which is allowed
  • You have been diagnosed with certain specific migraine or headache conditions, such as aura without headache, hemiplegic migraine, retinal migraine, or several other less common types (confirm with trial site)
  • You have a headache condition caused by another underlying illness or health problem, unless it is medication overuse headache, which is allowed
  • You are currently taking more than one prescribed medication to prevent migraines
  • You stopped taking a specific type of migraine prevention injection (anti-CGRP monoclonal antibody) less than 5 months before your screening appointment

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Merz Medical Expert, Merz Therapeutics

Phone: +49691503

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Merz Therapeutics GmbH
Registry
ClinicalTrials.gov
Start date
21 August 2025
Est. completion
1 March 2027

Where this trial is recruiting

🇦🇹 Austria 🇨🇦 Canada 🇨🇿 Czechia 🇩🇰 Denmark 🇫🇷 France 🇩🇪 Germany 🇮🇹 Italy 🇵🇱 Poland 🇸🇰 Slovakia 🇪🇸 Spain 🇨🇭 Switzerland 🇬🇧 United Kingdom 🇺🇸 United States

Primary endpoints

Change in monthly migraine days from baseline (28 days before baseline visit) to Month 6 (weeks 21 to 24 after first injection) - Dose A

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov